Hepatitis C and G
After the discovery of hepatitis B and A viruses in the 1960s and early 1970s, it became obvious there still were many cases of clinical viral hepatitis, particularly posttransfusion hepatitis, that could not be accounted for by either of these viruses. Hence, the term non-A, non-B hepatitis (NANBH) was coined to represent those as yet unidentified hepatitis viruses. In the late 1970s and early 1980s, a series of elegant experiments, done mainly by Bradley et al. at the Centers for Disease Control and Prevention (1,2), established the transmissibility and the physicochemical properties of this infectious parenteral NANB hepatitis agent. In 1986, inter-feron-alpha was reported to be useful in patients with chronic NANB hepatitis, even before the etiologic agent was identified. In 1989, the major parenteral NANB hepatitis agent, now designated as hepatitis C virus (HCV) was identified (3). The disease non-A, non-B hepatitis is now called hepatitis C.
KeywordsChronic Hepatitis Interferon Therapy Extrahepatic Manifestation NANB Hepatitis Hepatocellular Disease
Unable to display preview. Download preview PDF.
- 17.Shibata M, Morishima T, Kudo T. Serum hepatitis C virus sequences in posttransfusion non-A, non-B hepatitis. Blood 1991;15:1157–1160.Google Scholar
- 33.Martinot-Peignoux M, Marcellin P, Pouteau M. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050–1056.PubMedCrossRefGoogle Scholar
- 35.Bennett WG, Inoue Y, Beck JR. Justification of a single 60-month course of interferon (IFN) for histologically mild chronic hepatitis C. Hepatology 1995;22:290A.Google Scholar
- 37.Chazouilleres O, Kim M, Combs C. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenrol 1994; 106:994–999.Google Scholar